Shield Therapeutics plc Total Assets
Shield Therapeutics plc total assets. Based on the latest financial reports, Shield Therapeutics plc (STX) holds total assets worth GBX62.10 Million GBX (≈ $7.56K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Shield Therapeutics plc worth for the company's overall valuation and market capitalisation.
Total Assets of Shield Therapeutics plc (2013–2024)
Total assets of Shield Therapeutics plc from 2013 to 2024. This chart illustrates how Shield Therapeutics plc's total assets have evolved over time, based on quarterly financial data. See Shield Therapeutics plc (STX) share price today for real-time trading data and today's change.
Shield Therapeutics plc - Asset Composition Analysis
Shield Therapeutics plc Total Assets Breakdown (December 2024)
Shield Therapeutics plc total assets breakdown as of December 2024. Shield Therapeutics plc's total assets of GBX62.10 Million consist of 66.0% current assets and 34.0% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 12.2% |
| Accounts Receivable | GBX20.16 Million | 43.9% |
| Inventory | GBX4.52 Million | 9.9% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX14.51 Million | 31.6% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Shield Therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore STX working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shield Therapeutics plc's current assets represent 66.0% of total assets in 2024, a decrease from 80.8% in 2013.
- Cash Position: Cash and equivalents constituted 12.2% of total assets in 2024, down from 75.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 18.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 43.9% of total assets.
Shield Therapeutics plc Competitors by Total Assets
Key competitors of Shield Therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
Shield Therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.83 | 1.05 | 3.46 |
| Quick Ratio | 0.69 | 0.90 | 2.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-8.64 Million | GBX1.02 Million | GBX6.82 Million |
Shield Therapeutics plc - Advanced Valuation Insights
This section examines the relationship between Shield Therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 76.33 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -5.9% |
| Total Assets | GBX45.90 Million |
| Market Capitalization | $415.82K USD |
Valuation Analysis
Below Book Valuation: The market values Shield Therapeutics plc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shield Therapeutics plc's assets decreased by 5.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shield Therapeutics plc (2013–2024)
The table below shows the annual total assets of Shield Therapeutics plc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX45.90 Million ≈ $5.58K |
-5.95% |
| 2023-12-31 | GBX48.80 Million ≈ $5.94K |
+121.07% |
| 2022-12-31 | GBX22.07 Million ≈ $2.69K |
-50.30% |
| 2021-12-31 | GBX44.41 Million ≈ $5.40K |
+36.54% |
| 2020-12-31 | GBX32.53 Million ≈ $3.96K |
-10.44% |
| 2019-12-31 | GBX36.32 Million ≈ $4.42K |
-16.28% |
| 2018-12-31 | GBX43.38 Million ≈ $5.28K |
-3.53% |
| 2017-12-31 | GBX44.97 Million ≈ $5.47K |
-14.15% |
| 2016-12-31 | GBX52.38 Million ≈ $6.37K |
+1731.61% |
| 2015-12-31 | GBX2.86 Million ≈ $347.98 |
+184.86% |
| 2014-12-31 | GBX1.00 Million ≈ $122.16 |
-50.86% |
| 2013-12-31 | GBX2.04 Million ≈ $248.57 |
-- |
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the… Read more